Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02782182 · ClinicalTrials.gov registry record · Phase 1
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02782182: Clinical Trial Phase 1 study, sponsored by University of Chicago.
NCT02782182 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02782182, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.
Primary Outcome
Measured by percentage of successes/failures
Interventions
- DRUG FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-06-28 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 1 |
Why NCT02782182 stopped before completion
NCT02782182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) is the first listed.
NCT02782182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02782182 about?
NCT02782182 is a clinical study titled "Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study". The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.
What is the current status of trial NCT02782182?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-06-28. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT02782182?
The interventions under investigation include: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) (DRUG).
Who is sponsoring clinical trial NCT02782182?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02782182's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI